Contrast Sensitivity and Other Vision Tests in the Optic Neuritis Treatment Trial

Trobe, Jonathan D.; Beck, Roy W.; Moke, Pamela S.; Cleary, Patricia A.

doi:10.1016/s0002-9394(14)75429-7

Cited by 116 publications

(62 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The visual function was worse in both MS subgroups compared to controls. These data confirmed previous reports [12][13][14] , suggesting that chronic axon damage can occur in spite of episodes of acute ON, although stronger correlation was found in eyes with history of ON.…”

Section: Discussionsupporting

confidence: 92%

Visual pathway abnormalities were found in most multiple sclerosis patients despite history of previous optic neuritis

Castro

Damasceno

et al. 2013

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

ObjectiveIt was to investigate visual field (VF) abnormalities in a group of multiple sclerosis (MS) patients in the remission phase and the presence of magnetic resonance imaging (MRI) lesions in the optic radiations.MethodsVF was assessed in 60 participants (age range 20-51 years): 35 relapsing-remitting MS patients [20 optic neuritis (+), 15 optic neuritis (-)] and 25 controls. MRI (3-Tesla) was obtained in all patients.ResultsVisual parameters were abnormal in MS patients as compared to controls. The majority of VF defects were diffuse. All patients except one had posterior visual pathways lesions. No significant difference in lesion number, length and distribution was noted between patients with and without history of optic neuritis. One patient presented homonymous hemianopsia.ConclusionPosterior visual pathway abnormalities were found in most MS patients despite history of previous optic neuritis.

show abstract

Section: Discussionsupporting

confidence: 92%

Visual pathway abnormalities were found in most multiple sclerosis patients despite history of previous optic neuritis

Castro

Damasceno

et al. 2013

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…While some spontaneous remyelination occurs, most patients have residual structural and clinical deficits 1, 2, 3, 4. A physiological hallmark of AON is prolonged visual evoked potential (VEP) latency, resulting from persistent demyelination of the affected optic nerve 2, 5…”

Section: Introductionmentioning

confidence: 99%

Predictors of response to opicinumab in acute optic neuritis

Cadavid

Balcer

Galetta

et al. 2018

Ann Clin Transl Neurol

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups to identify participants more likely to benefit from opicinumab.Methods RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of the affected eye at 24 weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut‐off were evaluated in the per protocol population using analysis of covariance (ANCOVA); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was weight gain by treatment.ResultsTreatment benefit of opicinumab (n = 33) over placebo (n = 36) on the primary endpoint was greatest in participants older than the median age at baseline (≥33 years); the difference versus placebo for baseline age ≥33 years was −14.17 msec [P = 0.01] versus −0.89 msec for baseline age <33 years, [P = 0.87]). Post hoc analysis showed that VEP latency recovery was significantly associated with less RGCL/IPL thinning (P = 0.0164), occurring early on.InterpretationAge was the strongest prespecified baseline characteristic associated with a treatment effect of opicinumab. A strong association between VEP latency recovery at week 24 and early RGCL/IPL preservation was observed.

show abstract

“…[11][12][13] Grupların homojen seçilmemiş olması, kayıt ve uyarı şartlarındaki farklılıklarda diğer önemli sebepler arasındadır. Bizim çalışmamızın kısıtlayıcı yönleri ise MS tanısı almış hastalara, ek olarak kontrast duyarlılık muayenesinin yapılmaması ve PVEP testinin kontrast duyarlılık azaltılarak tekrarlanmamasıdır.…”

Section: Discussionunclassified

Subklinik Multipl Skleroz Hastalarının Desen Görsel Uyarılmış Potansiyeller ve Görme Alanı Testi ile Değerlendirilmesi

Bilgin¹,

İlker²,

Çavdar³

et al. 2014

tjo

View full text Add to dashboard Cite

Contrast Sensitivity and Other Vision Tests in the Optic Neuritis Treatment Trial

Cited by 116 publications

References 20 publications

Visual pathway abnormalities were found in most multiple sclerosis patients despite history of previous optic neuritis

Visual pathway abnormalities were found in most multiple sclerosis patients despite history of previous optic neuritis

Predictors of response to opicinumab in acute optic neuritis

Subklinik Multipl Skleroz Hastalarının Desen Görsel Uyarılmış Potansiyeller ve Görme Alanı Testi ile Değerlendirilmesi

Contact Info

Product

Resources

About